The stock of ACTELION LTD (OTCMKTS:ALIOF) registered a decrease of 43.82% in short interest. ALIOF’s total short interest was 91,400 shares in September as published by FINRA. Its down 43.82% from 162,700 shares, reported previously. With 400 shares average volume, it will take short sellers 229 days to cover their ALIOF’s short positions. The stock last traded at $168.3 per share. It is down 31.69% since February 8, 2016 and is uptrending. It has outperformed by 15.20% the S&P500.
Actelion Ltd is a Switzerland-based biopharmaceutical firm that focuses on the discovery, development and commercialization of drugs for diseases with unmet medical needs. The company has a market cap of $18.14 billion. The Firm specializes in the field of pulmonary arterial hypertension , a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. It currently has negative earnings. The Company’s portfolio of PAH treatments includes Opsumit (macitentan), Tracleer (bosentan), Uptravi (selexipag), Veletri (epoprostenol for injection) and Ventavis (iloprost).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.